- Home
- ETY vs AZTA Comparison
ETY vs AZTA Comparison
Compare ETY & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETY
- AZTA
- Stock Information
- Founded
- ETY 2006
- AZTA 1978
- Country
- ETY United States
- AZTA United States
- Employees
- ETY N/A
- AZTA N/A
- Industry
- ETY Finance Companies
- AZTA Industrial Machinery/Components
- Sector
- ETY Finance
- AZTA Technology
- Exchange
- ETY Nasdaq
- AZTA Nasdaq
- Market Cap
- ETY 2.4B
- AZTA 2.4B
- IPO Year
- ETY N/A
- AZTA 1995
- Fundamental
- Price
- ETY $15.28
- AZTA $53.82
- Analyst Decision
- ETY
- AZTA Buy
- Analyst Count
- ETY 0
- AZTA 5
- Target Price
- ETY N/A
- AZTA $61.60
- AVG Volume (30 Days)
- ETY 247.3K
- AZTA 521.7K
- Earning Date
- ETY 01-01-0001
- AZTA 02-05-2025
- Dividend Yield
- ETY 7.21%
- AZTA N/A
- EPS Growth
- ETY N/A
- AZTA N/A
- EPS
- ETY N/A
- AZTA N/A
- Revenue
- ETY N/A
- AZTA $656,323,000.00
- Revenue This Year
- ETY N/A
- AZTA N/A
- Revenue Next Year
- ETY N/A
- AZTA $6.32
- P/E Ratio
- ETY N/A
- AZTA N/A
- Revenue Growth
- ETY N/A
- AZTA N/A
- 52 Week Low
- ETY $10.59
- AZTA $38.82
- 52 Week High
- ETY $13.46
- AZTA $68.54
- Technical
- Relative Strength Index (RSI)
- ETY 60.16
- AZTA 65.07
- Support Level
- ETY $15.00
- AZTA $50.79
- Resistance Level
- ETY $15.24
- AZTA $53.39
- Average True Range (ATR)
- ETY 0.19
- AZTA 1.76
- MACD
- ETY 0.02
- AZTA -0.01
- Stochastic Oscillator
- ETY 92.06
- AZTA 77.92
About ETY Eaton Vance Tax-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Tax-mgd Dvsf Eq Inc Fd is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, and consumable fuels, and other sectors.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.